Source comparison
PT-141 Nasally vs Subcutaneously: Research Application Comparison
Nasal Spray 55–65% 30–60 minutes None Bypassed entirely Moderate (spray metering variability) Best for protocols requiring rapid onset without injection training. Accepts reduced bioavailability trade-off for convenience and reproducibility Subcutaneous Inject
This comparison does not assign a generated winner or score.
- Nasal Spray
- 55–65%
- 30–60 minutes
- None
- Bypassed entirely
- Moderate (spray metering variability)
- Best for protocols requiring rapid onset without injection training. Accepts reduced bioavailability trade-off for convenience and reproducibility
- Subcutaneous Injection
- ~90%
- 60–90 minutes
- Possible (erythema, localised swelling in 5–10% of administrations)
- Subject to hepatic peptidase activity post-absorption
- High (syringe measurement to 0.01 mL)
- Best for protocols prioritising maximum bioavailability and precise dose titration. Requires injection competency and sterile technique
- Oral (Not Viable)
- <5%
- N/A
- Extensive degradation by gastric acid and intestinal peptidases
- PT-141 is not orally bioavailable. Peptide bonds are cleaved in the GI tract before systemic absorption
- The trade-off isn't subtle. If your research protocol tolerates 30–35% lower bioavailability in exchange for faster onset and zero injection logistics, nasal is the correct choice. If maximum receptor saturation per milligram administered is the priority, subcutaneous wins despite the slower Tmax.